Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil

Circulation: Heart Failure

Volumn 6, Issue 4, 2013, Pages 694-702

  Sherrid, Mark V ^a   Shetty, Aneesha ^a   Winson, Glenda ^a   Kim, Bette ^a   Musat, Dan ^a,b   Alviar, Carlos L ^a   Homel, Peter ^a   Balaram, Sandhya K ^a   Swistel, Daniel G ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b Heart and Vascular Institute of New Jersey   (United States)

Author keywords

Cardiac surgical procedures; Cardiomyopathy, hypertrophic; Disopyramide; Drug therapy

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DISOPYRAMIDE; PYRIDOSTIGMINE; VERAPAMIL; ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ADD ON THERAPY; ADULT; AGED; ALCOHOL SEPTAL ABLATION; ARTICLE; CATHETER ABLATION; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DISEASE CONTROL; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MUSCLE RESECTION; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROVOCATION; REST; SUDDEN CARDIAC DEATH; SURVIVAL RATE; SYMPTOM; XEROSTOMIA; DRUG THERAPY; HEART SURGERY; HYPERTROPHIC CARDIOMYOPATHY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; TREATMENT FAILURE;

CARDIAC SURGICAL PROCEDURES; CARDIOMYOPATHY, HYPERTROPHIC; DISOPYRAMIDE; DRUG THERAPY;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIAC SURGICAL PROCEDURES; CARDIOMYOPATHY, HYPERTROPHIC; COMBINED MODALITY THERAPY; DISOPYRAMIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT FAILURE; VERAPAMIL;

EID: 84884715413     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.000122     Document Type: Article

References (30)

1. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232-2239.
2. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295-303.
3. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124: 2761-2796.
4. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED; Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687-1713.
5. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation. 1995;92:1680-1692.
6. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, Tome Esteban MT, McKenna WJ. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006;92:785-791.
7. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45:1251-1258.
8. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, Gersh BJ, Ackerman MJ, McCully RB, Dearani JA, Schaff HV, Danielson GK, Tajik AJ, Nishimura RA. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:470-476.
9. Sorajja P, Ommen SR, Holmes DR Jr, Dearani JA, Rihal CS, Gersh BJ, Lennon RJ, Nishimura RA. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126:2374-2380.
10. Balaram SK, Tyrie L, Sherrid MV, Afthinos J, Hillel Z, Winson G, Swistel DG. Resection-plication-release for hypertrophic cardiomyopathy: Clinical and echocardiographic follow-up. Ann Thorac Surg. 2008;86:1539-1544.
11. Ball W, Ivanov J, Rakowski H, Wigle ED, Linghorne M, Ralph-Edwards A, Williams WG, Schwartz L, Guttman A, Woo A. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol. 2011;58:2313-2321.
12. Alhaj EK, Kim B, Cantales D, Uretsky S, Chaudhry FA, Sherrid MV. Symptomatic exercise-induced left ventricular outflow tract obstruction without left ventricular hypertrophy. J Am Soc Echocardiogr. 2013;26:556-565.
13. Musat D, Joshi R, Obeleniene R, Bangalore S, Winson G, Castaneda V, Musat C, Chaudhry FA, Sherrid MV. Impact of acute response of obstructive hypertrophic cardiomyopathy to oral disopyramide and correlates of response. J Am Coll Cardiol. 2008;51:A61. Abstract.
14. Sherrid MV, Arabadjian M. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2012;54:483-492.
15. Teichman SL, Ferrick A, Kim SG, Matos JA, Waspe LE, Fisher JD. Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. J Am Coll Cardiol. 1987;10:633-641.
16. Maron BJ. Hypertrophic cardiomyopathy centers. Am J Cardiol. 2009;104:1158-1159.
17. Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation. 2003;108:2342-2348.
18. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56:1-120.
19. Finkelstein DM, Muzikansky A, Schoenfeld DA. Comparing survival of a sample to that of a standard population. J Natl Cancer Inst. 2003;95:1434-1439.
20. Minami Y, Kajimoto K, Kawana M, Hagiwara N, Sherrid MV. Synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy. Int J Cardiol. 2010;141:195-197.
21. McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, Schaff HV, Tajik AJ, Gersh BJ. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2007;28:2583-2588.
22. Olivotto I, Ommen SR, Maron MS, Cecchi F, Maron BJ. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol. 2007;50:831-834.
23. Sherrid MV, Pearle G, Gunsburg DZ. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation. 1998;97:41-47.
24. Kajimoto K, Imai T, Minami Y, Kasanuki H. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline. Am J Cardiol. 2010;106:1307-1312.
25. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981;64:437-441.
26. Nagueh SF, Groves BM, Schwartz L, Smith KM, Wang A, Bach RG, Nielsen C, Leya F, Buergler JM, Rowe SK, Woo A, Maldonado YM, Spencer WH 3rd. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. J Am Coll Cardiol. 2011;58:2322-2328.
27. Sherrid MV, Chaudhry FA, Swistel DG. Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction. Ann Thorac Surg. 2003;75: 620-632.
28. Iacovoni A, Spirito P, Simon C, Iascone M, Di Dedda G, De Filippo P, Pentiricci S, Boni L, Senni M, Gavazzi A, Ferrazzi P. A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. Eur Heart J. 2012;33:2080-2087.
29. ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, Serruys PW. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail. 2010;3:362-369.
30. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999;99:2927-2933.